Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-12-22
1996-03-26
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514392, 514913, A61K 31535, A61K 31415
Patent
active
055020526
ABSTRACT:
Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and other ophthalmic conditions are described. A method of controlling elevated intraocular pressure with those compositions is also described. The compositions contain a combination of an alpha-2 agonist (e.g., para-amino clonidine) and a beta blocker (e.g., betaxolol).
REFERENCES:
patent: 3468887 (1969-09-01), Stahle et al.
patent: 3852468 (1974-12-01), Howe et al.
patent: 4402974 (1983-09-01), Matier et al.
patent: 4428883 (1984-01-01), Hussein
patent: 4454154 (1984-06-01), Matier
patent: 4455317 (1984-06-01), Matier
patent: 4461904 (1984-07-01), York
patent: 4515800 (1985-05-01), Cavero et al.
patent: 4517199 (1985-05-01), York
patent: 4559359 (1985-12-01), Matier
patent: 4578403 (1986-03-01), Matier
patent: 4581376 (1986-04-01), Macri
patent: 4734438 (1988-03-01), Macri
AMA Drug evaluation, 2nd, 1973, pp. 675-686.
Sugar, The Ten Commandments for Management of Primary Open Angle Glaucoma-Sugar-Glaucoma 1(1)-1979-pp. 9-15 (1979).
Rouot, et al. "Clonidine and Related Analogues. Quantitative Correlations" J. Med. Chem., vol. 19, pp. 1049-1054 (1976).
Evans et al. "B-Adrenergic Receptor Blockers as Therapeutic Agents" Ann. Reports in Med. Chem., vol. 14, pp. 81-87 (1979).
Timmermans et al. "Structure-Activity Relationships in Clonidine-Like Imidazolidines and Related Compounds" Gustav Fischer Verlag (1980).
Schwartz, B., "Method of Treating Glaucoma with Corticosteroids and Adrenergic Drugs", Chemical Abstract, vol. 109, No. 7, issued 15 Aug. 1988, p. 76.
Machin et al. "B.sub.1 Selective Adrenoceptor Antagonists, 2,4-Ether-Linked Phenoxypropanolamines" J. Med. Chem., vol. 26, pp. 1570-1575 (1983).
Machin et al. "B.sub.1 Selective Adrenoceptor Antagonists, 3,4-Azolyl-Linked Phenoxypropanolamines" J. Med. Chem., vol. 27, pp. 503-509 (1984).
Pitha et al. "B-Adrenergic Antagonists with Multiple Pharmacophores: Persistent Blockade of Receptors" J. Med. Chem., vol. 26, pp. 7-11 (1983).
Kierstead et al., "B.sub.1 Selective Adrenoceptor Antagonists. 1, Synthesis and B-Adrenergic Blocking Activity of a Series of Binary (Aryloxy) Propanolamines" J. Med. Chem., vol. 26, pp. 1561-1569 (1983).
Erhardt et al. "Ultra-Short-Acting B-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of (Aryloxy) Propanolamines Having Esters on the Aryl Function" J. Med. Chem., vol. 26, pp. 1109-1112 (1983).
Baldwin et al. "B.sub.1 Selective Adrenoceptor Antagonists: Examples of the 2-4-3-(Substituted-amino)-2-hydroxypropoxy phenyl imidazole Class" J. Med. Chem., vol. 26, pp. 649-657 (1983).
McClure et al. "Antihypertensive B-Adrenergic Blocking Agents: N-Aralkyl Analogues of 2-3-(tert-Butylamino)-2-hydroxypropoxy-3-cyanopyridine" J. Med. Chem., vol. 26, pp. 649-657 (1983).
Large et al. "B-Adrenergic Blocking Agents. 23,1-(Substituted-amido) phenoxy-3-(substituted-amino) alkyl amino propan-2-ols" J. Med. Chem., vol. 26, pp. 352-357 (1983).
Allen, et al., "Additive Effect of Betaxolol and Epinephrine in Primary Open Angle Glaucoma", Archives of Ophthalmology, vol. 104, No. 7, Jul. 1986, pp. 1178-1184.
Leydhecker, W., "Augenheilkunde", 23rd Edition, Springer Verlag, pp. 165-171 (1987).
Schnarr, et al., "Wirksamkeit und Verta/ glichkeit Wirkstoffkombination von Timolol und Pilocarpin-Eine Pilostudie", Klin. Monatsbl. Augenheilk, 191(6), pp. 436-438 (1987).
Mehrotra, et al., "Compaative Evaluation of Pilocarpine 2% and combined Guanethidine 1% & Adrenaline 0.5% in the treatment of Chronic simple Glaucoma", Ind. J. Ophthal., vol. 35, No. 3, pp. 146-148 (1987).
Morrison, et al., "Adjunctive Glaucoma Therapy: A Comparison of Apraclonidine to Dipivefrin when Added to Timolol Maleate", Ophthalmology, vol. 96, No. 1, pp. 3-7 (1989).
Yaldo, et al. "Additive Effect of 1% Apraclonidine Hydrochroride to Nonselective .beta.-Blcokers", Ophthalmology, vol. 98, No. 7, pp. 1075-1078 (1991).
West, et al., "Therapeutic Response Interactions Between Timolol Maleate and Dipivefrin Hydrochloride", Australian and New Zealand Journal of Ophthalmology, vol. 15, pp. 131-134 (1987).
Burke, et al., "The Ocular Effects of Xylazine in Rabbits, Cats and Monkeys", Journal of Ocular Pharmacology, vol. 2, No. 1, pp. 9-20 (1986).
Stiegler, G., "Bupranolol-augentropfen (Ophtorenin.RTM.) in der Glaukom-Dauertherapie", Klin. Mbl. Augenheilk, 174, pp. 267-275 (1979) (including English translation).
Bunin, et al., "Modern Preparations for Treatment of Glaucoma (Review)", Khim. Farm., 2h. 21, No. 11 pp. 1395-1405 (1987) (including English translation).
Rompp Chemie Lexikon, p. 4406.
Keates, et al., "Safety and Effectiveness of Concomitant Administration of Dipivefrin and Timolol Maleate", American Journal of Ophthalmology, vol. 91, pp. 243-248 (1981).
Brown, et al., "ALO 2145 Reduces the Intraocular Pressure Elevation after Anterior Segment Laser Surgery", Ophthalmology, vol. 95, No. 3, pp. 378-384 (1988).
The 1986 Red Lists.
Nielsen, "TIMOLOL Hypotensive Effect, Used Alone and in Cmobination for Treatment of Increased Intraocular Pressure", Acta Ophthalmologica, vol. 56, pp. 504-509 (1978).
Fechner, Medikameto/ se Augentherapie.
Alcon Laboratories Inc.
Arno James A.
Brown Gregg C.
Fay Zohreh
LandOfFree
Use of a combination of apraclonidine and timolol to control int does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a combination of apraclonidine and timolol to control int, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a combination of apraclonidine and timolol to control int will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-915752